A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA209-906 (PRRIT)

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910